Company Profile: ADMA Biologics, Inc.
Background
ADMA Biologics, Inc. is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics. The company focuses on the prevention and treatment of infectious diseases in immunocompromised patients and others at risk for certain infections. ADMA's mission is to develop and commercialize plasma-derived human immune globulins targeted to specific patient populations for the treatment and prevention of certain infectious diseases and management of immune-compromised patient populations.
Key Strategic Focus
ADMA's strategic focus includes:
- Core Objectives: To develop and commercialize specialty biologic products for the treatment and prevention of infectious diseases in immunocompromised patients.
- Areas of Specialization: Plasma-derived immune globulin therapies.
- Key Technologies Utilized: Proprietary immunotechnology, including a microneutralization assay for measuring neutralizing antibodies in plasma donor samples.
- Primary Markets Targeted: Immunocompromised patients and individuals at risk for certain infections.
Financials and Funding
As of the latest available data, ADMA Biologics reported total revenue of approximately $510 million for the fiscal year 2025, with an adjusted EBITDA of around $235 million. The company has provided guidance for 2026, projecting total revenue of approximately $635 million and adjusted EBITDA of approximately $360 million.
Pipeline Development
ADMA is developing SG-001, a pre-clinical hyperimmune globulin targeting Streptococcus pneumoniae. The company anticipates generating initial proof-of-concept animal data for SG-001 by the end of 2025, with potential annual revenues of $300–500 million if successful.
Technological Platform and Innovation
- Proprietary Technologies: ADMA's proprietary immunotechnology includes a microneutralization assay that quantitatively measures titer levels of neutralizing antibodies in plasma donor samples.
- Significant Scientific Methods: The company employs a robust, sustainable, and controlled manufacturing process for producing its specialty biologic products.
Leadership Team
- Adam S. Grossman: Founder, Director, President, and Chief Executive Officer. Mr. Grossman founded ADMA Biologics in 2007 and has served as President and CEO since October 2011. He previously held roles at National Hospital Specialties and GenesisBPS.
Market Insights and Competitor Analysis
The global immunoglobulin market is valued at approximately $20.1 billion in 2025, with the intravenous immunoglobulin (IVIG) segment estimated at $13.2 billion. The market is projected to grow at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2033.
Key competitors include:
- CSL Behring: A global biotechnology leader with a significant presence in the plasma-derived therapeutics market.
- Grifols S.A.: A Spanish-based company specializing in plasma-derived medicines, including immunoglobulin therapies.
- Takeda Pharmaceutical Company: A global pharmaceutical company with a substantial portfolio in plasma-derived therapies.
Strategic Collaborations and Operational Insights
ADMA has engaged in strategic initiatives, including the divestiture of three plasma centers to enhance margins and supply visibility. The company has expanded its distribution network through agreements with partners like McKesson Specialty.
ADMA's vertically integrated approach, encompassing plasma collection, manufacturing, and commercialization, provides control over the supply chain, ensuring product quality and supply stability.
Strategic Opportunities and Future Directions
The company aims to leverage its proprietary technologies and manufacturing capabilities to expand its product portfolio, including the development of SG-001, and to increase market share by converting users to its premium product, ASCENIV.
Contact Information
- Official Website: ADMA Biologics
- Social Media Profiles:
- LinkedIn: ADMA Biologics LinkedIn
- Twitter: ADMA Biologics Twitter
Note: The above information is based on the latest available data as of March 6, 2026.
